Kamal Puri

Company: Oncoresponse

Job title: Chief Scientific Officer

Seminars:

Targeting Inhibitory Receptors on Myeloid Cells to Overcome Resistance to Immune Checkpoint Blockade 1:30 pm

– Using the human immune system to identify antibodies that modulate the tumor microenvironment – Discovery of anti-LILRB2/ILT4 lead antibody OR502 that rescue T cells from macrophage-mediated suppression – Preclinical characterization of OR641, a dual antagonist antibody targeting both LILRB1/ILT2 and LILRB2/ILT4Read more